期刊文献+

2011—2013年贵港市人民医院抗肿瘤药物的使用情况分析 被引量:1

Analysis on anticancer drugs used in Guigang City People's Hospital from 2011 to 2013
原文传递
导出
摘要 目的分析2011—2013年贵港市人民医院抗肿瘤药物的使用情况和用药趋势。方法通过回顾性检索贵港市人民医院HIS系统2011—2013年的数据,并对各类抗肿瘤药物的销售金额、销售量及构成比等进行统计。结果 2011—2013年抗肿瘤药物的销售金额逐年增大,尤其抗代谢药和植物来源抗肿瘤药及其衍生物的增长幅度较大,烷化剂类药物的销售金额却呈下降趋势。销售金额前3位的抗肿瘤药分别是吉西他滨、多西他赛、培美曲塞。销量最大的抗肿瘤药是氟尿嘧啶,其次是吉西他滨。结论贵港市人民医院抗肿瘤药物的销售金额增长率接近全国水平,抗代谢药和植物来源抗肿瘤药及其衍生物的市场需求大,应加大对其品种的生产和优化力度。 Objective To analyze the usage of anticancer drugs in Guigang City People’s Hospital from 2011 to 2013. Methods The data were drawn from the HIS system in the hospital retrospectively, and the consumption sum, sales volume, and component ratio of anticancer drugs were analyzed. Results Consumption sum of anticancer drugs increased year by year substantially during 2011-2013, especially antimetabolite and anticancer drugs from plants and their derivatives, but alkylating drugs showed a downward trend in demand. Consumption sum of top three drugs in anticancer drugs were gemcitabine, docetaxel, and pemetrexed. The largest sale of the anticancer drugs was fluorouracil, then was gemcitabine. Conclusion The growth rate of sales of anticancer drugs in Guigang City People’s Hospital closes to the national level. The antimetabolite and anticancer drugs from plants and their derivatives have a big demand in the market, therefore the varieties of production and optimization should be intensified.
作者 林洪奇
出处 《现代药物与临床》 CAS 2014年第10期1161-1164,共4页 Drugs & Clinic
关键词 抗肿瘤药物 用药金额 统计分析 anticancer drugs consumption sum statistical analysis
  • 相关文献

参考文献5

二级参考文献57

  • 1龚德根,郑鸿.健择联用HCPT治疗胰腺癌的临床观察[J].中华腹部疾病杂志,2003,3(8):570-571. 被引量:1
  • 2李兰芳,王华庆.小细胞肺癌的二线化疗及研究进展[J].肿瘤研究与临床,2006,18(6):424-426. 被引量:15
  • 3[1]Calvert H.An overview of folate metabolism:Features relevant to the action and toxicities of antifolate anticancer agents.Semin Oncol,1999,26 (2 Suppl 6):3
  • 4[2]Castagneto B,Mencoboni M,Degiovanni D,et al.Pemetrexed (MTA) and carboplatin (CBDCA) in the treatment of advanced pleural mesothelioma (MPM).Proc ASCO,2006,Abs 7093
  • 5[3]Marino A,Pinto C,Mutri V,et al.Neoadjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM):An Italian experience with cisplatin-based regimens.Proc ASCO,2006,Abs 17022
  • 6[4]Karthaus M,Frieler F,Vasquez N,et al.Pemetrexed(A) /platinum for patients with advanced malignant peritoneal mesothelioma (AbM):The Bielefeld Experience.Proc ASCO,2006,Abs 4151
  • 7[5]Simon GR,Janne PA,Langer C,et al.A.Dowlati,et al.A finalized phase Ⅱ report of pemetrexed (P) plus gemcitabine (G) as front -line chemotherapy for patients with peritoneal mesothelioma (PM).Proc ASCO,2006,Abs 2050
  • 8[6]Demarinis F,Paul S,Hanna N,et al.Survival update for the phase Ⅲ study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC).Proc ASCO,2006,Abs 7133
  • 9[7]Fossella FV,Berry DA,Adachi S,et al.Survival in previously treated advanced NSCLC:Pemetrexed versus best supportive care (BSC).Proc ASCO,2006,Abs 17015
  • 10[8]West HJ,Belt RJ,Wakelee HA,et al.Front line therapy with gemcitabine (G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC):Final report of a phase Ⅱ clinical trial.Proc ASCO,2006,Abs 7116

共引文献51

同被引文献8

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部